• GPR107 Loss Promotes Diabetic Nephropathy

  2026-09-25

  Xu et al. report that GPR107 deficiency worsens diabetic kidney injury by impairing clathrin-mediated internalization of AT1R in podocytes, shifting collagen IV production and degradation toward extracellular accumulation. The findings connect receptor trafficking to glomerular basement membrane remodeling and suggest a mechanism to test in future diabetic nephropathy research.

• Losartan Beyond Blood Pressure: Testing Matrix Biology

  2026-09-25

  Losartan is more than an angiotensin II receptor antagonist for hypertension research: its use in a tumor hydrogel study raises new questions about how to measure extracellular-matrix remodeling. Explore the study’s practical assay implications, experimental limits, and ways to interpret Losartan’s effects across cardiovascular and tumor biology.

• Dexamethasone Workflows for Inflammation Research

  2026-09-24

  Build more interpretable inflammation assays with practical Dexamethasone treatment, vehicle-control, and readout strategies. The workflow connects glucocorticoid signaling studies with a recent natural-product macrophage study—while keeping their evidence and potency claims distinct.

• Angiotensin III: Practical RAAS Assay Workflows

  2026-09-24

  Use Angiotensin III to probe aldosterone release, receptor signaling, and a newly reported angiotensin-peptide effect on spike–receptor binding. This workflow-oriented guide separates established RAAS biology from exploratory assay recommendations and shows how to handle the peptide for reproducible results.

• Acetylcholine Chloride for Reproducible Assays

  2026-09-23

  Learn how to use Acetylcholine Chloride (SKU B1596) as a controlled cholinergic stimulus in cell-based and neuroscience workflows without confusing receptor activation with a viability readout. Practical guidance covers experimental controls, handling, interpretation of gut–brain findings, and product selection.

• JNJ-26481585 (Quisinostat) Research Workflows

  2026-09-23

  Learn how to deploy JNJ-26481585 (Quisinostat) as an epigenetic modulator for apoptosis, proliferation, and drug-resistance studies. This workflow connects HDAC inhibition with the TRIM21–ERK1/2 axis while emphasizing assay controls, formulation, and troubleshooting.

• SU6656: From Src Biology to Translational Strategy

  2026-09-22

  SU6656 is more than a catalog-listed Src tyrosine kinases inhibitor: it is a mechanistic probe connecting Src-regulated proliferation, megakaryocyte polyploidization, endothelial survival, and tumor vascular response. This thought-leadership article translates the available evidence into a disciplined framework for platelet-production research, cancer research, and radiotherapy development while distinguishing validated findings from forward-looking experimental opportunities.

• SCH772984 HCl: ERK1/2 Inhibitor Workflows

  2026-09-22

  SCH772984 HCl provides a nanomolar, mechanism-focused way to suppress ERK1/2 signaling in BRAF- and RAS-driven cancer models while enabling carefully timed studies of TERT regulation in human pluripotent stem cells. This guide connects pathway inhibition with phosphorylation, proliferation, chromatin, and transcriptional readouts, plus practical controls for reproducible experiments.

• Evacetrapib and the Ferroptosis Threshold

  2026-09-21

  A translational framework for interpreting hydrogen sulfide–driven ferroptosis in non-small cell lung cancer and positioning Evacetrapib (LY2484595) as an exploratory orthogonal reagent rather than an overclaimed pathway substitute.

• ACE Inhibitor Selectivity for Aminopeptidases

  2026-09-21

  This 1992 study systematically compared metallopeptidase inhibitors against the cell-surface aminopeptidases AP-A, AP-N, and AP-W. Its findings separated genuinely selective inhibitors from compounds whose apparent effects could reflect off-target aminopeptidase inhibition, providing an important framework for interpreting ACE inhibitor pharmacology and peptide-metabolism experiments.

• Bestatin Hydrochloride: From Peptidase to Assay Logic

  2026-09-20

  Bestatin hydrochloride, also known as Ubenimex, is more than a dual exopeptidase inhibitor. This article explains how its context-dependent effects on peptide processing can sharpen experimental design across angiogenesis inhibition, tumor biology, and neuropeptide signaling research.

• Angiotensin II: From GPCR Signal to Metabolic Phenotype

  2026-09-19

  Angiotensin II research increasingly depends on connecting receptor signaling with measurable metabolic and stress phenotypes. This guide uses the miR-1268a/CD36 heart-failure study to show how Angiotensin II models can be selected, controlled, and interpreted more rigorously.

• Mechanisms of Cell Death in Heart Disease: A Review

  2026-09-18

  The reference review reframes cardiac injury by showing that necrosis, like apoptosis, can be actively regulated rather than being purely passive. Its analysis connects death-receptor, mitochondrial, and endoplasmic-reticulum pathways and explains why cell-death mechanisms are relevant to myocardial infarction and heart failure research.

• Novobiocin: From Mechanism to Translation

  2026-09-18

  Novobiocin is an aminocoumarin antibiotic with a translational profile that spans bacterial DNA gyrase inhibition, Hsp90-dependent parasite biology, and emerging antiviral research. This article interprets the evidence, defines practical experimental gates, and outlines how researchers can move from concentration-response data to credible development decisions.

• ACE2 Peptidase Specificity and Angiotensin (1-7)

  2026-09-17

  Saulnier and colleagues used a fluorogenic ACE2 activity assay to define how angiotensin peptide length and terminal residues influence competition with an ACE2 substrate. Their findings identify Ang II and Ang III as the most effective natural ACE2 substrates in this assay and clarify why Angiotensin (1-7) is primarily a product rather than a competing substrate.

7769 records 1/518 page Next 12345 下5页 Last page